This study introduces the pulmonary vein isolation outcome degree (PVIOD) as a new semiquantitative measure for the efficacy of atrial fibrillation (AF) catheter ablation and reports the determination of predictors associated with PVIOD. The median follow-up periods of 117 patients after the first and last ablation were, respectively, 82 (IQR 15) and 72 (IQR 30) months. PVIOD 1 included 32.5% of patients, those with successful single pulmonary vein isolation (PVI); PVIOD 2 included 29.1% of subjects, those with success after multiple procedures; PVIOD 3 comprised 14.5% of patients, those with clinical success; and PVIOD 4 included 23.9% of cases, those with procedural and clinical failure. In the multivariate ordinal logistic regression ana...
Introduction: Preprocedural factors may be helpful in selecting patients with atrial fibrillation (A...
AIMS: Transcatheter pulmonary vein ablation is the current treatment of choice for symptomatic drug-...
BACKGROUND: The Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II (S...
AIMS: Catheter ablation of paroxysmal atrial fibrillation (AF) reduces AF recurrence, AF burden, and...
PURPOSE:Catheter ablation of atrial fibrillation (AF) is an effective therapy for selected groups of...
SummaryBackgroundControversy exists as to whether atrial fibrillation (AF) ablation guided solely by...
The relationship between pulmonary vein (PV) anatomy and successful catheter ablation of atrial fibr...
AIMS: In patients with paroxysmal atrial fibrillation (PAF) the pattern of atrial fibrillation (AF) ...
AIMS: Pulmonary vein antrum isolation (PVAI) is the cornerstone of atrial fibrillation (AF) ablation...
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder in adults. Currently, ...
Cilj. Ova studija je imala za cilj da primeni novu semikvantitativnu meru za procenu ishoda radiofre...
Atrial fibrillation (AF) is an extensively studied arrhythmia that has a significant impact on morbi...
Background: Ablation index (AI) is a new lesion quality marker that has been demonstrated to allow a...
Background Catheter ablation for persistent atrial fibrillation (AF) is associated with less favorab...
Background: The use of the Ablation Index (AI) software for paroxysmal atrial fibril-lation (AF) has...
Introduction: Preprocedural factors may be helpful in selecting patients with atrial fibrillation (A...
AIMS: Transcatheter pulmonary vein ablation is the current treatment of choice for symptomatic drug-...
BACKGROUND: The Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II (S...
AIMS: Catheter ablation of paroxysmal atrial fibrillation (AF) reduces AF recurrence, AF burden, and...
PURPOSE:Catheter ablation of atrial fibrillation (AF) is an effective therapy for selected groups of...
SummaryBackgroundControversy exists as to whether atrial fibrillation (AF) ablation guided solely by...
The relationship between pulmonary vein (PV) anatomy and successful catheter ablation of atrial fibr...
AIMS: In patients with paroxysmal atrial fibrillation (PAF) the pattern of atrial fibrillation (AF) ...
AIMS: Pulmonary vein antrum isolation (PVAI) is the cornerstone of atrial fibrillation (AF) ablation...
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder in adults. Currently, ...
Cilj. Ova studija je imala za cilj da primeni novu semikvantitativnu meru za procenu ishoda radiofre...
Atrial fibrillation (AF) is an extensively studied arrhythmia that has a significant impact on morbi...
Background: Ablation index (AI) is a new lesion quality marker that has been demonstrated to allow a...
Background Catheter ablation for persistent atrial fibrillation (AF) is associated with less favorab...
Background: The use of the Ablation Index (AI) software for paroxysmal atrial fibril-lation (AF) has...
Introduction: Preprocedural factors may be helpful in selecting patients with atrial fibrillation (A...
AIMS: Transcatheter pulmonary vein ablation is the current treatment of choice for symptomatic drug-...
BACKGROUND: The Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial Part II (S...